June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
ERG Findings after One Year Intravitreal Ranibizumab and Single or Multiple Spot Panphotocoagulation Treatment for Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • Katharina Messias
    Ophthalmology, Ribeirão Preto School of Medicine, Ribeirao Preto, Brazil
  • Rafael de Montier Barroso
    Ophthalmology, Ribeirão Preto School of Medicine, Ribeirao Preto, Brazil
  • Fabiano Sakamoto
    Ophthalmology, Ribeirão Preto School of Medicine, Ribeirao Preto, Brazil
  • Vinicius Monteiro de Castro
    Ophthalmology, Ribeirão Preto School of Medicine, Ribeirao Preto, Brazil
  • Amanda Marega
    Ophthalmology, Ribeirão Preto School of Medicine, Ribeirao Preto, Brazil
  • Rodrigo Jorge
    Ophthalmology, Ribeirão Preto School of Medicine, Ribeirao Preto, Brazil
  • Andre Messias
    Ophthalmology, Ribeirão Preto School of Medicine, Ribeirao Preto, Brazil
  • Footnotes
    Commercial Relationships Katharina Messias, None; Rafael de Montier Barroso, None; Fabiano Sakamoto, None; Vinicius Castro, None; Amanda Marega, None; Rodrigo Jorge, None; Andre Messias, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 764. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katharina Messias, Rafael de Montier Barroso, Fabiano Sakamoto, Vinicius Monteiro de Castro, Amanda Marega, Rodrigo Jorge, Andre Messias; ERG Findings after One Year Intravitreal Ranibizumab and Single or Multiple Spot Panphotocoagulation Treatment for Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):764. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the effects of intravitreal Ranibizumab (IVR) associated or not with panphotocoagulation (PRP) using single (EDTRS) or multiple (pattern scan laser - PASCAL) spot targeting laser on retinal function in proliferative diabetic retinopathy.

Methods: A total of 44 patients have been enrolled in this randomized, prospective clinical trial, and assigned to treatment with only IVR, IVR-PASCAL or IVR-EDTRS. Comprehensive ophthalmological evaluations were performed at baseline and every 4 weeks after treatment including full-field electroretinography (ERG) using a recording protocol in accordance with the ISCEV standard, to measure a- and b-wave amplitude and implicit time for dark-adapted 0.01 cd.s/m2 (Rod) and 3.0 cd.s/m2 (CR); and light-adapted 3.0 cd.s/m2 (Cone) single flash and 30 Hz flicker, and LED full-field stimulator, first using red (635 to 638 nm), then blue (465 to 470 nm), and then white (6500 K) stimulus, with 5 minutes inter-session interval at baseline and at 12, 24 and 48 weeks after treatment (Espion E2 - Diagnosys LLC, Lowell, MA). PRP was performed exclusively at baseline in 2 sessions. In eyes with macular edema, macular short-pulse grid laser was associated to IVR at baseline. IVR was repeated monthly if central subfield macular thickness measured with SDOCT was higher than 300 µm, or quarterly if neovascularization was detected by angiography.

Results: IVR=13, PASCAL=14, and ETDRS=13 eyes finished the 48 weeks follow-up. No significant difference was observed between groups for any ERG parameters at baseline. A significant amplitude reduction was observed dark and light adapted ERG stimuli, for EDTRS and PASCAL groups, but not for IVR, up to 48 weeks. No difference was observed between EDTRS and PASCAL groups regarding ERG amplitude reduction. There was no significant correlation between ERG amplitude or amplitude reduction and OCT macular thickness or visual acuity.

Conclusions: These data indicate that single spot or PASCAL laser PRP associated to IVR cause similar ERG amplitude reductions, which is not observed with IVR alone, up to one year follow-up.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×